AbbVie seeks OK for new hepatitis C drug

SHARE AbbVie seeks OK for new hepatitis C drug

AbbVie Inc. has applied for U.S. approval of a new treatment for hepatitis C.

The North Chicago-based drugmaker said Tuesday testing of the new drug involved more than 2,300 patients in 25 countries. AbbVie expects to seek approval in the European Union in May.

“This (New Drug Application) submission is a significant advancement for AbbVie’s HCV development program,” said Dr. Scott Brun, the company’s vice president of pharmaceutical development. “We believe our all-oral, interferon-free regimen holds the potential to be a promising new therapy for patients living with this chronic infection.”

The company says about 3.2 million people in the U.S. live with the hepatitis C virus.

AbbVie to move 2,000 employees off North Chicago campus

Drugmaker AbbVie to set up plant in Singapore

AbbVie earnings hurt by generic drugs

The Latest
Peggy Dula’s $3,600 charge was far higher than what her two siblings were charged for their ambulance rides, though they were also in her car during a crash and were taken to the same hospital.
Mary Gonzalez, 81, is helping lead the push to close the polluting scrap-metal shredding operation owned by Sims Metal Management.
Those issuing voter registration and ballot challenges say they are worried about election fraud. Right. If there’s a scam afoot, it’s the goodwill and concern they claim in the guise of “election integrity.”
Blazingly original Netflix film blends music, narrative and trippy visuals to depict an artist’s search for romance.